Streetbeat News

Revenues

BNTX

MRNA

PFE

Moderna Inc. is engaged in a patent trial in London against Pfizer Inc. and BioNTech SE over the use of mRNA technology in COVID-19 vaccines. Moderna alleges patent infringement, while Pfizer and BioNTech contest the claim. The trial could impact future mRNA technology use and financial compensations. Moderna seeks royalties from Pfizer and BioNTech's vaccine, Comirnaty, to offset declining sales of its own vaccine, Spikevax. The outcome may influence global intellectual property disputes and the development of mRNA-based treatments.

Portfolio Pulse from Vandana Singh

April 23, 2024 | 7:00 pm

CRK

Analyst evaluations of Comstock Resources (NYSE:CRK) over the last three months show a mix of opinions, with recent actions including both upgrades and downgrades. The average 12-month price target is now $9.5, a decrease from $9.86. The company faces challenges such as a significant revenue decline of -55.49% as of December 31, 2023, below-average net margin and ROE, and a high debt-to-equity ratio, indicating potential financial difficulties.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 7:00 pm

CART

In the past three months, Maplebear (NASDAQ:CART) received 10 analyst ratings, showing a mix of bullish to bearish sentiments. The average 12-month price target is $41.0, indicating an 18.12% increase from the previous target of $34.71. Analysts have adjusted their ratings and price targets, reflecting their evolving expectations for Maplebear, which operates as Instacart. The company has shown a revenue growth rate of 6.08% as of December 31, 2023, a net margin of 16.56%, and an impressive ROE of 3.68%, despite lagging behind industry peers in revenue growth.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 6:01 pm

TCRX

TScan Therapeutics (NASDAQ:TCRX) received mixed analyst ratings with an updated average 12-month price target of $10.75, marking a 53.57% increase from the previous target. Analysts from Wedbush, Barclays, and HC Wainwright & Co. have maintained or raised their ratings, reflecting optimism in TCRX's market performance. The company, focusing on T-cell receptor engineered T cell therapies for cancer, shows substantial market capitalization and revenue growth but has a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 6:01 pm

EVRI

Everi Holdings Inc (NYSE:EVRI) has received mixed reviews from analysts, with recent evaluations showing a unanimous indifferent stance. The average 12-month price target for EVRI has been lowered to $12.25, indicating a negative sentiment shift. Despite facing revenue challenges and a market cap below industry averages, Everi Hldgs showcases strong financial performance with notable net margin, ROE, and ROA figures. The company operates in the gaming and financial technology sectors, providing a range of services and products to the casino industry.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 6:01 pm

PNFP

Analyst reviews for Pinnacle Financial Partners (PNFP) show a mix of bullish to bearish sentiments, with recent actions including ratings adjustments and price target changes. The average 12-month price target is $96.5, reflecting a 6.63% increase from the previous $90.50. The company's financial performance indicates challenges in revenue growth and asset utilization but shows strong profitability with a high net margin.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 6:00 pm

ANIP

ANI Pharmaceuticals (NASDAQ:ANIP) has been positively evaluated by 5 analysts, with recent ratings showing a bullish outlook. The average 12-month price target has been raised to $77.8, indicating a 9.19% increase from the previous target. Analyst actions include maintaining and raising price targets, reflecting optimism about the company's performance. ANI Pharmaceuticals has shown impressive financial performance with significant revenue growth, efficient cost management, and strong financial health, outperforming industry benchmarks.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 6:00 pm

BEAM

Beam Therapeutics (NASDAQ:BEAM) received mixed analyst ratings with an updated average 12-month price target of $46.2, reflecting a 52.32% increase from the previous target. Analysts from Wedbush, BMO Capital, Barclays, RBC Capital, and JP Morgan provided insights, with some maintaining their ratings and others raising their price targets. The company's financial health appears strong, with significant revenue growth, high net margin, and solid ROE and ROA, indicating a robust market position and operational efficiency.

Portfolio Pulse from Benzinga Insights

April 23, 2024 | 6:00 pm

BLDR

Builders FirstSource shares are trading higher due to better-than-expected new home sales data, positively impacting building products companies.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 5:56 pm

RTX

RTX Corporation (NYSE:RTX) reported a first-quarter FY24 adjusted net sales increase of 12% Y/Y to $19.3 billion, surpassing the consensus of $18.4 billion. Adjusted EPS rose 10% Y/Y to $1.34, beating the consensus of $1.23. The company reiterated its FY24 outlook, expecting sales of $78 billion-$79 billion and adjusted EPS of $5.25-$5.40. RTX's operating cash flow for the quarter was $0.3 billion, with a free cash outflow of $(0.1) billion. The backlog at the end of the quarter stood at $202 billion. RTX also entered into an energy supply agreement with ENGIE Resources LLC, a subsidiary of ENGIE North America.

Portfolio Pulse from Lekha Gupta

April 23, 2024 | 5:49 pm